(Philadelphia,
PA) - Richard Aplenc, MD, MSCE, has been appointed
an Assistant Professor in the Department of Pediatrics,
division of Pediatric Oncology, at the University of
Pennsylvania School of Medicine.
Dr. Aplenc earned his medical degree in 1994 from the
University of Virginia. He earned his Masters of Science
in Clinical Epidemiology at the University of Pennsylvania,
and is currently pursuing a Doctoral Program in the
same area there.
Dr. Aplenc's research interests include the molecular
epidemiology of childhood cancers, with a focus on case
control studies to evaluate the role of polymorphisms
in drug metabolizing enzymes, and treatment outcome
and toxicity in pediatric leukemia. He is currently
working on several research projects studying genotypes
and cancer. Dr. Aplenc is also collaborating with Dr.
Jason Christie, also of the Center for Clinical Epidemiology
and Biostatistics at the University of Pennsylvania,
in a cohort study examining genetic modifiers of acute
lung injury susceptibility and outcome. His research
has been published in several journals including the
Best Practice & Research Clinical Haematology,
Accepted Genetics, Clinical Cancer Research, Cancer
Research, and Leukemia.
Dr. Aplenc is a member of the American Association for
Cancer Research, the American Society of Hematology
and the American Society of Clinical Oncology. He is
also an ad-hoc reviewer for the publications Cancer,
Clinical Cancer Research and Medical and Pediatric
Oncology.
# # #
.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.